Article Sidebar
Main Article Content
Abstract
Background: Pathogenic variants in the GNAO1 gene have been previously linked to severe epileptic encephalopathy, severe progressive movement disorders, developmental delay, and intellectual disability.
Method: report of 2 cases.
Results: we present 2 unrelated girls, an 18-year-old, and a 4.5-year-old, with mild phenotypes. While each was noted early on to have hypotonia, failure to thrive, and developmental delay, they both have made significant progress with various therapeutic interventions. Neither have had any developmental regression, seizures or choreoathetosis.
Conclusion: these 2 cases further expand the phenotype spectrum of GNAO1 mutations, which is important for counseling and to help guide management plans.
Article Details
Copyright (c) 2020 Amal Abu Libdeh, Albert Chang
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Authors who publish with this journal agree to the following terms:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
References
- Nakamura K, Kodera H, Akita T, et al. De novo mutations in GNAO1, encoding a galphao subunit of heterotrimeric G proteins, cause epileptic encephalopathy. Am J Hum Genet. 2013;93(3):496-505. doi: 10.1016/j.ajhg.2013.07.014 [doi].
- Saitsu H, Fukai R, Ben-Zeev B, et al. Phenotypic spectrum of GNAO1 variants: Epileptic encephalopathy to involuntary movements with severe developmental delay. Eur J Hum Genet. 2016;24(1):129-134. doi: 10.1038/ejhg.2015.92 [doi].
- Feng H, Sjogren B, Karaj B, Shaw V, Gezer A, Neubig RR. Movement disorder in GNAO1 encephalopathy associated with gain-of-function mutations. Neurology. 2017;89(8):762-770. doi: 10.1212/WNL.0000000000004262 [doi].
- Pearson TS, Helbig I. Epileptic encephalopathy, movement disorder, and the yin and yang of GNAO1 function. Neurology. 2017;89(8):754-755. doi: 10.1212/WNL.0000000000004277 [doi].
- Kulkarni N, Tang S, Bhardwaj R, Bernes S, Grebe TA. Progressive movement disorder in brothers carrying a GNAO1 mutation responsive to deep brain stimulation. J Child Neurol. 2016;31(2):211-214. doi: 10.1177/0883073815587945 [doi].
- Sakamoto S, Monden Y, Fukai R, et al. A case of severe movement disorder with GNAO1 mutation responsive to topiramate. Brain Dev. 2017;39(5):439-443. doi: S0387-7604(16)30194-2 [pii].
- Dhamija R, Mink JW, Shah BB, Goodkin HP. GNAO1-Associated Movement Disorder. Mov Disord Clin Pract. 2016;3(6):615–617. Published 2016 Mar 11. doi:10.1002/mdc3.12344
- Koy A, Cirak S, Gonzalez V, et al. Deep brain stimulation is effective in pediatric patients with GNAO1 associated severe hyperkinesia. J Neurol Sci. 2018;391:31-39. doi: S0022-510X(18)30242-9 [pii].
- Schorling DC, Dietel T, Evers C, et al. Expanding phenotype of de novo mutations in GNAO1: Four new cases and review of literature. Neuropediatrics. 2017;48(5):371-377. doi: 10.1055/s-0037-1603977 [doi].
- Danti FR, Galosi S, Romani M, et al. GNAO1 encephalopathy: Broadening the phenotype and evaluating treatment and outcome. Neurol Genet. 2017;3(2):e143. doi: 10.1212/NXG.0000000000000143 [doi].
- Retterer, K., Juusola, J., Cho, M. et al. Clinical application of whole-exome sequencing across clinical indications. Genet Med 18, 696–704 (2016). https://doi.org/10.1038/gim.2015.148
- Lek, M., Karczewski, K., Minikel, E. et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature 536, 285–291 (2016). https://doi.org/10.1038/nature19057
References
Nakamura K, Kodera H, Akita T, et al. De novo mutations in GNAO1, encoding a galphao subunit of heterotrimeric G proteins, cause epileptic encephalopathy. Am J Hum Genet. 2013;93(3):496-505. doi: 10.1016/j.ajhg.2013.07.014 [doi].
Saitsu H, Fukai R, Ben-Zeev B, et al. Phenotypic spectrum of GNAO1 variants: Epileptic encephalopathy to involuntary movements with severe developmental delay. Eur J Hum Genet. 2016;24(1):129-134. doi: 10.1038/ejhg.2015.92 [doi].
Feng H, Sjogren B, Karaj B, Shaw V, Gezer A, Neubig RR. Movement disorder in GNAO1 encephalopathy associated with gain-of-function mutations. Neurology. 2017;89(8):762-770. doi: 10.1212/WNL.0000000000004262 [doi].
Pearson TS, Helbig I. Epileptic encephalopathy, movement disorder, and the yin and yang of GNAO1 function. Neurology. 2017;89(8):754-755. doi: 10.1212/WNL.0000000000004277 [doi].
Kulkarni N, Tang S, Bhardwaj R, Bernes S, Grebe TA. Progressive movement disorder in brothers carrying a GNAO1 mutation responsive to deep brain stimulation. J Child Neurol. 2016;31(2):211-214. doi: 10.1177/0883073815587945 [doi].
Sakamoto S, Monden Y, Fukai R, et al. A case of severe movement disorder with GNAO1 mutation responsive to topiramate. Brain Dev. 2017;39(5):439-443. doi: S0387-7604(16)30194-2 [pii].
Dhamija R, Mink JW, Shah BB, Goodkin HP. GNAO1-Associated Movement Disorder. Mov Disord Clin Pract. 2016;3(6):615–617. Published 2016 Mar 11. doi:10.1002/mdc3.12344
Koy A, Cirak S, Gonzalez V, et al. Deep brain stimulation is effective in pediatric patients with GNAO1 associated severe hyperkinesia. J Neurol Sci. 2018;391:31-39. doi: S0022-510X(18)30242-9 [pii].
Schorling DC, Dietel T, Evers C, et al. Expanding phenotype of de novo mutations in GNAO1: Four new cases and review of literature. Neuropediatrics. 2017;48(5):371-377. doi: 10.1055/s-0037-1603977 [doi].
Danti FR, Galosi S, Romani M, et al. GNAO1 encephalopathy: Broadening the phenotype and evaluating treatment and outcome. Neurol Genet. 2017;3(2):e143. doi: 10.1212/NXG.0000000000000143 [doi].
Retterer, K., Juusola, J., Cho, M. et al. Clinical application of whole-exome sequencing across clinical indications. Genet Med 18, 696–704 (2016). https://doi.org/10.1038/gim.2015.148
Lek, M., Karczewski, K., Minikel, E. et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature 536, 285–291 (2016). https://doi.org/10.1038/nature19057